Oncology Drugs Market Size, Growth & Forecast to 2020
Oncology Drugs Market is Expected to Reach $111.9 Billion, Globally, by 2020. Read more at: https://www.alliedmarketresearch.com/oncology-cancer-drugs-market Augmentation in the prevalence and incidence rate of various cancers, growing popularity of biological and targeted modalities, along with the patent expiration of major cancer drugs are expected to drive the growth of global oncology drugs market. However, high initial capital investment in new drug development, long-term side effects associated with chemotherapy, and high cost of advanced therapies (targeted and immunotherapies) would limit the growth of the market.
Oncology Drugs Market is Expected to Reach $111.9 Billion, Globally, by 2020. Read more at: https://www.alliedmarketresearch.com/oncology-cancer-drugs-market
Augmentation in the prevalence and incidence rate of various cancers, growing popularity of biological and targeted modalities, along with the patent expiration of major cancer drugs are expected to drive the growth of global oncology drugs market. However, high initial capital investment in new drug development, long-term side effects associated with chemotherapy, and high cost of advanced therapies (targeted and immunotherapies) would limit the growth of the market.
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Global<br />
<strong>Oncology</strong>/Cancer<br />
<strong>Drugs</strong> <strong>Market</strong><br />
<strong>Forecast</strong><br />
2013 - <strong>2020</strong><br />
Published Date: 24 Feb 2015 No. of pages : 159
<strong>Oncology</strong> <strong>Drugs</strong> <strong>Market</strong> Scenario<br />
‣ <strong>Oncology</strong> <strong>Drugs</strong> <strong>Market</strong> is Expected <strong>to</strong> Reach $111.9 Billion, Globally, by <strong>2020</strong>, registering a<br />
CAGR of 7.1% from 2014 <strong>to</strong> <strong>2020</strong>.<br />
‣ Increase in adoption of combination therapies instead of traditional cy<strong>to</strong><strong>to</strong>xic therapies is a<br />
major fac<strong>to</strong>r that contributes <strong>to</strong> the market growth.<br />
‣ The combinational therapies which include targeted therapy and immunotherapy (Biologic<br />
therapy), is expected <strong>to</strong> witness ~10% surge in its market share collectively by <strong>2020</strong>.<br />
‣ Augmentation in the prevalence and incidence rate of various cancers, growing popularity of<br />
biological and targeted modalities, along with the patent expiration of major cancer drugs<br />
are expected <strong>to</strong> drive the growth of global oncology drugs market.<br />
‣ However, high initial capital investment in new drug development, long-term side effects<br />
associated with chemotherapy, and high cost of advanced therapies (targeted and<br />
immunotherapies) would limit the growth of the market.
<strong>Oncology</strong> <strong>Drugs</strong> <strong>Market</strong> Key Segments<br />
Therapeutic Modalities<br />
• Chemotherapy<br />
• Targeted Therapy<br />
• Immunotherapy (Biologic Therapy)<br />
• Hormonal Therapy<br />
• Others<br />
Cancer Types<br />
• Blood Cancer<br />
• Breast Cancer<br />
• Gastrointestinal Cancer<br />
• Prostate Cancer<br />
• Respira<strong>to</strong>ry/Lung Cancer<br />
• Skin Cancer<br />
• Other Cancers
<strong>Oncology</strong> <strong>Drugs</strong> <strong>Market</strong> is further bifurcated based on<br />
‣ The global oncology drugs market is experiencing a shift in therapeutic modalities i.e. from<br />
traditional cy<strong>to</strong><strong>to</strong>xic agents <strong>to</strong> newly develop targeted and immunotherapeutic modalities.<br />
‣ Tumor cell specificity, an attribute of aforementioned modality, has reduced drug remission<br />
rates and has rendered an enhanced rate of survival in cancer patients thus, complementing<br />
the market growth.<br />
‣ chemotherapeutic modalities would continue <strong>to</strong> be the leading therapeutic modality<br />
segment owing <strong>to</strong> its higher adoption rate and economic pricing.<br />
‣ Going forward, the demand for the chemotherapy modality might confront a negative<br />
influence due <strong>to</strong> marginal efficacy and chronic side effects such as anemia.<br />
‣ Amongst these different cancer types, blood cancer was the largest revenue generating<br />
segment in 2015. The growth of blood cancer segment is majorly due <strong>to</strong> the high cost of the<br />
drugs used <strong>to</strong> treat blood cancer.
<strong>Oncology</strong> <strong>Drugs</strong> <strong>Market</strong> Drivers And Restraints<br />
Drivers<br />
‣ Rising incidence and prevalence of various cancer types<br />
‣ Growing importance of biological and targeted drug therapies<br />
‣ Expiration of key patents and Biosimilars impact<br />
‣ Acquisitions and collaborations bolt-on strategies driving the market growth<br />
Restraints<br />
‣ High cost of drug development and threat of failure<br />
‣ Adverse effects of anti-cancer drug therapy
Key Benefits<br />
Immunotherapy/biological drugs segment expected <strong>to</strong> grow<br />
at a double digit CAGR during the forecast period and would<br />
grow at the fastest rate<br />
Blood cancer is the major revenue generating segment in the<br />
global oncology drug application market however, lung cancer<br />
segment is expected <strong>to</strong> grow fastest among all<br />
Currently, North America garners a major share in the<br />
oncology drugs market, in terms of market size<br />
Asia Pacific oncology drug market is dominated by China and<br />
Japan, <strong>to</strong>gether contributing <strong>to</strong> ~60% of the regional market<br />
revenue in 2014
<strong>Oncology</strong> <strong>Drugs</strong> <strong>Market</strong> By Geography<br />
North America, Europe, Asia Pacific, LAMEA
Key Players Operating in <strong>Oncology</strong> <strong>Drugs</strong> <strong>Market</strong><br />
1. Roche diagnostics<br />
2. Novartis AG<br />
3. Celgene Corporation<br />
4. AstraZeneca<br />
5. Johnson & Johnson<br />
6. Merck & Co.<br />
7. Eli Lilly & Co.<br />
8. Amgen Inc.<br />
9. Pfizer<br />
10. GlaxoSmithKline
Thank You!<br />
For More Details<br />
Visit us at<br />
https://www.alliedmarketresearch.com/oncology-cancerdrugs-market<br />
Follow Us On
Change language